Related Experiment Video
Updated: Mar 14, 2026
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
Platelet Function Testing-Guided Antiplatelet Therapy
Ekaterina Lenk1, Michael Spannagl2
1Verum Diagnostica GmbH, Roche Professional Diagnostics , Munich, Germany.
Insights
Platelet function testing identifies patients inadequately responding to antiplatelet drugs, enabling personalized treatment to reduce ischemic events and improve cardiovascular outcomes.
Area of Science:
- Cardiology
- Vascular Biology
- Pharmacology
Background:
- Cardiovascular diseases are a leading cause of death, with vascular disorders increasing due to aging, lifestyle, diabetes, and dyslipidemia.
- Platelet activation contributes to arterial thrombus formation, leading to occlusive vascular events like myocardial infarction and stroke.
- Current antiplatelet therapies (aspirin, clopidogrel) have variable efficacy, with a subset of patients ('non-responders') facing higher ischemic risks.
Purpose of the Study:
- To evaluate the clinical utility of platelet function (PF) testing in optimizing antiplatelet therapy.
- To determine if personalized antiplatelet strategies guided by PF tests improve patient outcomes and safety.
- To address the challenges posed by non-response to standard antiplatelet treatments and the limitations of newer agents.
Main Methods:
- Review of evidence from randomized studies and recent research on tailored antiplatelet therapies.
- Analysis of the role of platelet function diagnostics in identifying patient subgroups.
- Consideration of cost-effectiveness and bleeding risk associated with different antiplatelet agents and testing strategies.
Main Results:
- Platelet function testing can identify patients with inadequate response to antiplatelet therapy, who are at increased risk for ischemic complications.
- Tailored antiplatelet strategies, guided by PF diagnostics, have shown association with improved patient outcomes.
- Despite initial uncertainty from randomized trials, a consensus expert opinion now supports the clinical adoption of PF diagnostics.
Conclusions:
- Platelet function testing is valuable for personalizing antiplatelet therapy, enhancing efficacy, and improving patient safety.
- PF diagnostics can guide the selection of optimal antiplatelet agents, balancing efficacy and bleeding risk.
- The clinical practice should incorporate PF diagnostics to manage patients at risk for cardiovascular events more effectively.
Abstract:
Cardiovascular diseases are the leading cause of death in the Western world. Several factors have led to the increase in vascular disorders, including the aging population, unhealthy lifestyles, increasing rates of diabetes and raised lipids, and further risk factors resulting in inflammation and calcification of the vascular endothelium. Activated platelets in damaged blood vessels can trigger arterial thrombus formation, leading to vascular occlusion with subsequent organ hypoperfusion and clinical manifestation of myocardial infarction, stroke, or peripheral artery disease. Platelet inhibitors such as aspirin and clopidogrel (Plavix(®) and generics) are prescribed as primary or secondary prevention to attenuate chronic platelet activation. However, a significant proportion of patients do not respond adequately to uniform antiplatelet treatment. These 'non-responders' have an increased risk for stent thrombosis, stroke, and other ischemic complications. Platelet function (PF) tests can identify these patients thus enabling physicians to offer personalized and alternative treatment strategies. Recent alternatives to clopidogrel include prasugrel (Efient(®)) and ticagrelor (Brilique(®)) - that are both more potent than clopidogrel but also more expensive and associated with a higher risk of bleeding complications. Given these drawbacks, PF testing might help clinicians to prescribe optimal antiplatelet agent to maximize patient safety and efficacy while minimizing costs. While randomized studies using different test systems have left clinicians puzzled about the medical value of tailored antiplatelet therapy, accumulated evidence from recent studies on tailored antiplatelet therapies and the association with improved outcomes have now resulted in a consensus expert opinion for the specific adoption of PF diagnostics into clinical practice.
More Related Videos
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:22Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:18Structure and Function of Platelets
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
01:27Peripheral Artery Disease III: Interprofessional Care